Stock Info
NEW RELEASES
EVENTS
STAY UPDATED
CORPORATE PRESENTATION
ANALYST COVERAGE
Palisade Bio is followed by the analysts listed here. Please note that any opinions, estimates or forecasts regarding Palisade Bio’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Palisade Bio or its management. Palisade Bio does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
COMPANY
Palisade Bio is a clinical-stage biopharmaceutical company developing differentiated oral therapeutics for immune-mediated and fibrotic diseases.
Our lead program, PALI-2108, is advancing in inflammatory bowel disease, with a Phase 2 study in ulcerative colitis and a planned Phase 2 study in Crohn’s disease.